Digital support for antidepressant pharmacotherapy in adults with depressive disorders: a systematic review of effectiveness, safety, and care-delivery models
Pharmacy and Intelligent healthcare · 04.08.2026
DOI: 10.68786/fiiz5 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Pharmacy and Intelligent healthcare, erschienen am 04.08.2026. Verfasst von Yu Tihonova und 3 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.
Abstract (Originalsprache)
Introduction
Initiation and adjustment of antidepressant therapy require regular assessment of treatment adherence, medication tolerability, and changes in depressive symptoms. Digital communication channels, mobile applications, telemedicine-based models, and clinical decision support systems may facilitate such monitoring; however, their effectiveness largely depends on personalized feedback and specialist involvement.
Aim
To summarize the evidence on the effectiveness, safety, and organizational models of digital pharmaceutical support for adults with depressive disorders. A systematic review was conducted in accordance with the PRISMA 2020 guidelines. The qualitative synthesis included 8 randomized controlled trials, while an additional 6 systematic reviews and meta-analyses were analyzed to contextualize the findings. The interventions included remote multidisciplinary care, secure messaging, mobile applications, systems for personalized antidepressant selection, and physician-prescribed digital therapeutics. The most consistent findings concerned improved adherence and continuity of treatment. Specialist-supported secure messaging increased the proportion of patients continuing treatment for more than 3 months from 61% to 81%. The PETRUSHKA system reduced treatment discontinuation from 27% to 17%, including discontinuation due to adverse reactions from 16% to 9%. Automated messaging without specialist involvement did not produce a significant effect. The effects of pharmacogenomics-guided systems and digital therapeutics on clinical response and remission were modest and heterogeneous. No Russian studies meeting the eligibility criteria were identified.
Conclusion
A hybrid model appears to be the most appropriate approach: the digital service monitors medication use, symptoms, and adverse reactions; a healthcare professional provides personalized feedback and facilitates patient referral; and the treating physician makes decisions regarding treatment adjustment. Russian randomized controlled trials are required to evaluate the effectiveness of this model.
Zitieren
APA
Tihonova, Y., Savchenko, D., Galuzina, I., & Kinkul'kina, M. (2026). Digital support for antidepressant pharmacotherapy in adults with depressive disorders: a systematic review of effectiveness, safety, and care-delivery models. Pharmacy and Intelligent healthcare. https://doi.org/10.68786/fiiz5
Vancouver
Tihonova Y, Savchenko D, Galuzina I, Kinkul'kina M. Digital support for antidepressant pharmacotherapy in adults with depressive disorders: a systematic review of effectiveness, safety, and care-delivery models. Pharmacy and Intelligent healthcare. 2026. doi:10.68786/fiiz5
BibTeX
@article{Tihonova2026,
author = {Tihonova, Yu and Savchenko, D and Galuzina, I and Kinkul'kina, M},
title = {Digital support for antidepressant pharmacotherapy in adults with depressive disorders: a systematic review of effectiveness, safety, and care-delivery models},
journal = {Pharmacy and Intelligent healthcare},
year = {2026},
doi = {10.68786/fiiz5}
}
EUVIMED